Details for Patent: 8,071,579
✉ Email this page to a colleague
Which drugs does patent 8,071,579 protect, and when does it expire?
Patent 8,071,579 protects ZEJULA, AKEEGA, LYNPARZA, and RUBRACA, and is included in five NDAs.
This patent has eighty-six patent family members in thirty-eight countries.
Summary for Patent: 8,071,579
| Title: | DNA damage repair inhibitors for the treatment of cancer |
| Abstract: | The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein. |
| Inventor(s): | Ashworth; Alan (London, GB), Jackson; Stephen (Cambridge, GB), Martin; Niall (Cambridge, GB), Smith; Graeme (Cambridge, GB) |
| Assignee: | The Institute of Cancer Research: Royal Cancer Hospital (London, GB) Kudos Pharmaceuticals Limited (Cambridge, GB) |
| Application Number: | 11/001,474 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,071,579
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ZEJULA | niraparib tosylate | CAPSULE;ORAL | 208447-001 | Mar 27, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS | ⤷ Try a Trial | ||||
| Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-001 | Aug 11, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION | ⤷ Try a Trial | ||||
| Janssen Biotech | AKEEGA | abiraterone acetate; niraparib tosylate | TABLET;ORAL | 216793-002 | Aug 11, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION | ⤷ Try a Trial | ||||
| Astrazeneca | LYNPARZA | olaparib | TABLET;ORAL | 208558-001 | Aug 17, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,071,579
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0327844.7 | Dec 1, 2003 |
International Family Members for US Patent 8,071,579
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 508118 | ⤷ Try a Trial | |||
| Austria | 521341 | ⤷ Try a Trial | |||
| Australia | 2004220321 | ⤷ Try a Trial | |||
| Australia | 2004294790 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
